Who are ETV or TDF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Emtricitabine / Tenofovir Disoproxil Pill, Doravirine (DOR), Emtricitabine/tenofovir disoproxil fumarate, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Etravirine (ETR), Emtricitabine and Tenofovir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etv-or-tdf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ETV or TDF — Competitive Intelligence Brief

ETV or TDF (ETV or TDF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease.

phase 2 Nucleoside reverse transcriptase inhibitor (NRTI) HIV-1 reverse transcriptase Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

ETV or TDF (ETV or TDF) — Tasly Tianjin Biopharmaceutical Co., Ltd.. Inhibits viral replication

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ETV or TDF TARGET	ETV or TDF	Tasly Tianjin Biopharmaceutical Co., Ltd.	phase 2	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Oral Tablet	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
ViiV Healthcare · 2 drugs in this class
Nanfang Hospital, Southern Medical University · 2 drugs in this class
Asan Medical Center · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Fu-Sheng Wang · 1 drug in this class
Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ETV or TDF — Competitive Intelligence Brief. https://druglandscape.com/ci/etv-or-tdf. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab